<i>LPA</i> Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels
Lipoprotein(a) [Lp(a)] levels are an independent risk factor for coronary artery disease (CAD). Two single-nucleotide polymorphisms (rs10455872, rs3798220) and number of KIV-2 repeats in the gene encoding Lp(a) (<i>LPA</i>) are associated with Lp(a) and CAD. Our aim was to investigate wh...
Main Authors: | Andreja Rehberger Likozar, Aleš Blinc, Katarina Trebušak Podkrajšek, Miran Šebeštjen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Journal of Cardiovascular Development and Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2308-3425/8/12/181 |
Similar Items
-
Lipoprotein(a) Gene Polymorphism Increases a Risk Factor for Aortic Valve Calcification
by: Ugur Ozkan, et al.
Published: (2019-08-01) -
The Influence of Treatment with PCSK9 Inhibitors and Variants in the <i>CRP</i> (rs1800947), <i>TNFA</i> (rs1800629), and <i>IL6</i> (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels
by: Tina Levstek, et al.
Published: (2022-04-01) -
Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
by: Andreja Rehberger Likozar, et al.
Published: (2022-12-01) -
Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors
by: Andreja Rehberger Likozar, et al.
Published: (2023-08-01) -
Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
by: Katja Hrovat, et al.
Published: (2022-07-01)